Recommendation 20a	All people living with active (newly diagnosed or relapsed) EGPA should be considered as having potentially life- or organ-threatening disease (GRADE 1C, SoA 99%).
Recommendation 20 b	All people living with active EGPA should be assessed for induction of remission treatment with GC combined with other immunomodulatory agents (GRADE 1C, SoA 99%).
Recommendation 20c	The recommended immunomodulatory options for people with life- or organ-threatening EGPA are intravenous pulse CYC as first line OR RTX if CYC is either contraindicated or not acceptable to the patient (GRADE 1C, SoA 98%).
Recommendation 20d	Anti-IL-5/IL-5R directed therapies (both ligand and receptor) have demonstrated broad efficacy in EGPA and are recommended (if available for any of the licensed indications) for remission induction in non-life or non-organ-threatening disease (GRADE 1A, SoA 98%).
Recommendation 20e	In non-life- or organ-threatening active EGPA, alternative induction therapy with MTX, MMF or AZA may be considered when anti-IL-5/IL-5R is not available or as adjunctive therapy depending on disease phenotype (GRADE 2C, SoA 98%).